Can patient involvement in early dialogues increase the value of the advice given? Moderator: Micholas Brooke, PARADIGM & PFMD Speakers: Nicholas Brooke, PARADIGM & PFMD Magie Galbraith, HAS / EUnetHTA



PARADIGM

- A Distinct Voice In the Patient Engagement Landscape

Mission

Contribute to a sustainable framework that enables meaningful patient engagement (PE) and demonstrates 'return on engagement' for all players

Research and priority setting



clinical trials

Early dialogues with regulators and HTA bodies



Objectives

Develop processes and tools for these three points in the medicine lifecycle Develop a sustainability roadmap for patient engagement



Multi-stakeholder collaboration

to drive meaningful and systematic patient engagement





4

A Virtuous Development Process



Collaborative Initiatives Dedicated to Patient Engagement

	PATIENT FOCUSED MEDICINES DEVELOPMENT	Pelenta Active in Research and Dialogues for an Improved Conversion of Medicines	EUPATI
•	Global Focus	European Focus	European Focus
<	Patient Engagement Guidance & Tools	Patient Engagement Guidance & Tools	Patient Capability Building
4	Full Medicine Lifecycle	Time Points: Research Prioritization; Clinical Trials; Early Dialogue Regulatory & HTA Bodies	Full Medicine Lifecycle
Ð	No Time Boundary	30 Months Duration	No Time Boundary
	http://patientfocusedmedicine.o rg/our-partners/	http://imi-paradigm.eu/project- partners/	https://www.eupati.eu/supporte rs-of-eupati/



HTAI HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL

Patient involvement in Early Dialogues

Neil Bertelsen,

Chair HTAi Patient & Citizen Involvement in HTA Interest Group

Why do we involve patients in HTA?



The HTAi values and standards looked at this issue from the HTA assessment point in time

Relevance	Fairness	Equity	Legitimacy	Capacity building
Patients have knowledge, perspectives and experiences that are unique and contribute to essential evidence for HTA.	Patients have the same rights to contribute to the HTA process as other stakeholders and have access to processes that enable effective engagement.	Patient involvement in HTA contributes to equity by seeking to understand the diverse needs of patients with a particular health issue, balanced against the requirements of a health system that seeks to distribute resources fairly among all users.	Patient involvement facilitates those affected by the HTA recommendations/d ecision to participate in the HTA; contributing to the transparency, accountability and credibility of the decision-making process.	Patient involvement processes address barriers to involving patients in HTA and build capacity for patients and HTA organizations to work together.

https://htai.org/interest-groups/pcig/values-and-standards/

What about during Early Dialogues?



Early dialogues...

... are years before a HTA decision-making point

... are about complex decisions on study designs

... when there is little available evidence


... and are confidential discussions

Is patient involvement at this point in time appropriate?

How can it be implemented?

How can it add value?

Does it really make a difference?



NICE National Institute for Health and Care Excellence

Scientific Advice at NICE; rationale for patient involvement

Heidi Livingstone, Senior Public Involvement Adviser

© NICE 2018. All rights reserved. Subject to notice of rights.

Why do companies seek NICE Scientific Advice?

A: to increase: the likelihood that the company's clinical development studies and other plans meet NICE evidence requirements

How does it help if patients participate in NICE Scientific Advice projects?

A: because it increases: the likelihood that the company's clinical development studies and other plans meet the needs of patients


NICE

Why do we involve patients in Scientific Advice?




NICE

Stages of patient involvement




14



Scientific Advice Face to Face Meetings

NICE

Typical Issues Raised for NICE Scientific Advice where patients can help.



NICE

How patients can help with quality of life – when and what to measure

Varies from condition to condition:

- cannot complete EQ5D data during an attach or episode and may have to capture it retrospectively
- suggested measuring quality of life weekly, for other conditions monthly was considered manageable
- suggested it would be needed only once and at what point that should be

Additional types of measures suggested:

- tiredness additional questionnaire (interrupted sleep, insomnia, fatigue)
- cognitive function

1	
=	
	====
=	
V	

17

Other examples of what patients can bring




• Why a tablet might not be an option for patients with certain conditions

- Why the six minute walk test doesn't mean much to patients
- Why some population groups, or individuals, might not want a particular treatment

NICE

NICE

Feedback



NICE

NICE National Institute for Health and Care Excellence

Thank you!

© NICE 2018. All rights reserved. Subject to notice of rights.

19



European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Maggie Galbraith Haute Autorité de Santé EUnetHTA ED Secretariat

European

Principles of patient involvement in EUnetHTA EDs

- > Patient perspective essential for EUnetHTA EDs:
 - At the time forming the advice
 - Respect Conflict of Interest and Confidentiality rules
- Providing unique insight of living with the condition to ensure recommendations meet patient's need
 - Advising on the signs and symptoms that have the greatest impact on their functional and psychological aspects of living
 - Impact on quality of life for patients and carers
 - > (available) treatment & treatment expectation
- Acceptability to participate in the proposed trial



eunethta

European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Testing 3 possible approaches

Approach	Patient contribution deliverables
Approach 1: Individual patient/patient's representative - interviewed regarding the disease and their experience	 Minutes of the interview Mention of patient contribution in final EUnetHTA recommendations Feedback questionnaire
Approach 2: Approach 1 + discussion with local HTAB regarding submission file (without applicant)	 Minutes of the interview Mention of patient contribution in final EUnetHTA recommendations Feedback questionnaire
Approach 3: Patient expert; Approach 1 + discussion with all participating HTABs regarding the submission file and participation in the F2F meeting with the Applicant	 Minutes of the interview Review final EUnetHTA recommendations Feedback questionnaire
Contact Strate S	

EUnetHTA experience thus far...

10 of 14 completed EUnetHTA EDs with patient contribution following the 3 approaches:

- 1. 6 interviews with patients (France, UK, Spain)
- 2. 8 interviews with a national patient representative (German patients' representative involved in any ED in which G-BA participates)
- 3. 4 EU patient representatives participating to overall ED process



е

Method

An analysis based on feedback collected from 7 patients:

- 1. 5 patients (3 French, 1 Spanish and 1 English) (approach 1)
- 2. 1 German representative patient (approach 2)
- 3. 1 EU representative (approach 3)

Approach 1: Individual patient/patient's representative - interviewed regarding the disease and their experience

Approach 2: Approach 1 + discussion with local HTAB regarding submission file (without Applicant)

Approach 3: Patient expert; Approach 1 + discussion with all participating HTABs regarding the submission file and participation in the F2F meeting with the Applicant



European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Preparation for the ED

Feedback	Proposal for improvement
While 5/7 patients never received training - Quite clear information in ED general objectives • 4/7 very satisfied • 2/7 mostly not; 1/7 not informed at all	 Training: using different tools (EUPATI, national training tool) and supports A list of definitions at the beginning of the questionnaire
 Quite clear understanding of what is expected from them 5/7 yes completely 1/7 mostly not 	

eunethta

As a reminder, all patients have been contacted by a patients' organisation



Interviews

Feedback	Proposal for improvement
 Positive feedback on the phone interview, and their overall interaction with EUnetHTA Large use of the questionnaire to prepare the interview (5/7 used it) Appreciate open questions with opportunity to develop topics at their convenience 	Translation of the questionnaire in native language for HTAi questionnaire and feedback questionnaire
 Patient had enough opportunities to express their opinion Quite confident of the impact of their contribution 	
Further access to Briefing Book and final recommendations requested	 Briefing Book at disposal of interested individual patient? List of Issue and Final recommendations to be shared Systematically with patients representatives



European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Face-to-face meeting

Feedback	Proposal for improvement
 Interest in participating in F2F	 Participation to F2F meeting
(because of the psychological impact	proposed to individual/national
of their physical presence) Appreciate the opportunities for	representative with simultaneous
reactive statement	translation



European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Time investment and administrative tasks

Feedback	Proposal for improvement
Clear understanding of the confidentiality agreement	
No difficulties to complete the DOICU and contract documents	
Investment: minimum of half day to review the Briefing Book and only few hours to prepare the interview	
No major burden of administrative task but still possibilities for improvement	Clarify payment and exchanges via IT system



European network for Health Technology Assessment | JA3 2016-2020 | www.eunethta.eu

Thank you!

EUnetHTA ED Secretariat: eunethta-has@has-sante.fr

HTAI HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL

Patient involvement in Early Dialogues

Neil Bertelsen,

Chair HTAi Patient & Citizen Involvement in HTA Interest Group

PARADIGM workshop on ED




 On 19th October 2018, eleven representatives from HTA bodies came together to discuss patient involvement in Early Dialogues, the current challenges in implementing patient involvement and the potential solutions (agencies from UK, Canada, Norway, Sweden, Spain, Italy, France and EUnetHTA)

The rationale for involving patients and/or advocates in the early dialogue process	The current challenges of initiating a patient involvement process in ED	The current experience of involving patients and the challenges that have been identified so far	The resources or tools that would be useful in solving the identified challenges
---	--	---	---


Agencies attending were very supportive of patient involvement in ED





But they hear a lot of objections and there are implementation challenges





So to make patient involvement in Early Dialogues a reality we need...





Create consistency and predictability across patient involvement in ED processes Have a menu of methodologies and approaches that could be applied Set a baseline standard of patient involvement in Early Dialogues

Areas of immediate need



Standard, generic tools that can be shared across HTA bodies...

Ř	Patient finding and recruitment	 Patient finding case studies Patient consent process Patient capability criteria guidance Patient guidance and ethical guidance
	Guidance and standards on patient interviews	 Standard interview templates and guidance, adaptable for each ED Guidance on skills needed for the interviewer
\star	Minimum standards framework	 Framework of methods with guidance Guidance for chairs

If any of you have examples of tools and resources in these areas (not necessarily for HTA or ED), then please share them if possible (<u>nb@neilbertelsen.com</u>)





